布地奈德联合喘可治注射液雾化吸入治疗支气管哮喘的临床疗效及对患者血清炎性因子的影响

Clinical Efficacy of Atomized Inhalation of Budesonide Combined with Chuankezhi Injection in the Treatment of Bronchial Asthma and Its Impact on Patients'Serum Inflammatory Factors

目的探讨布地奈德联合喘可治注射液雾化吸入治疗支气管哮喘的临床疗效及对患者血清炎性因子的影响。方法92例支气管哮喘患者随机分为两组各46例,对照组给予布地奈德雾化吸入治疗,试验组给予布地奈德联合喘可治注射液雾化吸入治疗,比较两组的临床疗效及治疗前后的血清炎性因子水平。结果试验组的治疗总有效率为95.65%,显著高于对照组的82.61%(P<0.05)。治疗后,试验组的IFN-γ水平显著高于对照组,ECP、IL-4水平显著低于对照组(P<0.05)。结论布地奈德联合喘可治注射液雾化吸入治疗支气管哮喘患者的临床疗效显著,可有效改善机体炎性反应。

Objective To explore the clinical efficacy of atomized inhalation of budesonide combined with Chuankezhi injection in the treatment of bronchial asthma and its impact on patients'serum inflammatory factors.Methods 92 patients with bronchial asthma were randomly divided into two groups,with 46 cases in each group.The cotnrol group was treated with atomized inhalation of budesonide,while the experimental group was treated with atomized inhalation of budesonide combined with Chuankezhi injection.The clinical efficacy and the levels of serum inflammatory factors before and after treatment were compared between two groups.Results The total effective rate of experimental group was 95.65%,significantly higher than 82.61%of control group(P<0.05).After treatment,the level of IFN-γof experimental group was significantly higher than that of control group,and the levels of ECP and IL-4 were significantly lower than those of control group(P<0.05).Conclusions Atomized inhalation of budesonide combined with Chuankezhi injection in the treatment of patients with bronchial asthma has significant clinical efficacy,and can effectively improve the inflammatory response of the body.